Latest Life Sciences News

Page 1 of 21
BCAL Diagnostics is prepared to support an expedited Genetic Signatures and Microba merger, but only on revised terms, a GSS board reset and protections for a superior proposal. It may also provide up to $2 million in working capital to Microba, subject to raising the funds itself.
Ada Torres
Ada Torres
19 Nov 2026
Genetic Signatures has abandoned its proposed merger with Microba Life Sciences after Microba said it lacked the financial capacity to complete the transaction without fresh capital. GSS also declined to provide unsecured working capital funding, leaving the shareholder vote and Takeovers Panel process to be unwound separately.
Ada Torres
Ada Torres
18 Nov 2026
Genetic Signatures has ended its proposed merger with Microba Life Sciences after Microba said it could not complete the transaction without raising more capital. The decision also removes the deal’s shareholder vote and leaves a Takeovers Panel application awaiting clarification.
Ada Torres
Ada Torres
18 Nov 2026
Vitrafy says it has moved from cryopreservation research into commercial execution, with 19 Guardion devices built, new US partnerships and $38.3 million in cash and term deposits. The next test is converting partner evaluations into recurring revenue after a planned FDA Class II listing in the coming weeks.
Victor Sage
Victor Sage
17 Nov 2026
Microba Life Sciences has been suspended from trading after revised terms for its proposed Genetic Signatures merger left it unable to complete the second tranche of its institutional placement. The company says it is assessing alternative funding while its cashflow runway narrows.
Victor Sage
Victor Sage
17 Nov 2026
Revvity has set out a long-range growth strategy built around AI-enabled scientific discovery, recurring software revenue and specialised diagnostics. The plan includes double-digit adjusted EPS growth, margin expansion and about US$5 billion of capital capacity through 2031, but formal 2027 guidance is still pending.
Ada Torres
Ada Torres
14 Nov 2026
BCAL Diagnostics, an 18.46% shareholder of Genetic Signatures, has asked the Takeovers Panel to intervene over the proposed merger with Microba Life Sciences. The application alleges the deal structure and shareholder process lack adequate protections, although no Panel has yet been appointed and no decision has been made.
Ada Torres
Ada Torres
13 Nov 2026
Genetic Signatures’ proposed Microba merger faces a formal challenge from 18.46% shareholder BCAL Diagnostics, which alleges the process lacks adequate protections and information for GSS investors. The Takeovers Panel has not yet appointed a sitting Panel or decided whether to open proceedings.
Ada Torres
Ada Torres
13 Nov 2026
EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
Victor Sage
Victor Sage
10 Nov 2026
STERIS delivered 9% second-quarter revenue growth and lifted its fiscal 2027 adjusted EPS outlook, helped partly by tariff refunds. Life Sciences led the operating gains, while weaker cash flow and a new restructuring plan add important qualifications.
Ada Torres
Ada Torres
5 Nov 2026
Revvity has lifted its full-year 2026 outlook after reporting stronger third-quarter revenue, organic growth and profitability. The life sciences and diagnostics group is also preparing to sell its China immunodiagnostics business for up to US$200 million.
Ada Torres
Ada Torres
4 Nov 2026
Waters delivered a stronger-than-expected third quarter, lifting every component of its 2026 guidance while organic growth accelerated across instruments, consumables and reagents. The company also acquired MOBILion Systems to extend its mass spectrometry technology into proteomics.
Sophie Babbage
Sophie Babbage
4 Nov 2026

Browse the archive

Full archive